Louis Kayitalire, a medical oncologist, has been appointed chief medical officer at Nanobiotix SA which is developing radioenhancers for the treatment of cancer. Dr Kayitalire joins from F-star biotechnology, a UK developer of bispecific antibodies for cancer. He has also held leadership positions at Bristol-Myers Squibb Co and Eli Lilly and Co where he helped drive product registrations for two widely-used chemotherapy drugs and the checkpoint inhibitor Opdivo.
Dr Kayitalire received his medical degree from Butare University in Rwanda and completed his training in oncology and haematology at the Gustave- Roussy Cancer Center in France.
Nanobiotix announced the appointment on 5 September 2023.
Copyright 2023 Evernow Publishing Ltd.